Prof Ranjit Manchanda

Professor and Consultant Gynaecological Oncologist
Profile Photo for Professor Ranjit Manchanda

Professor Ranjit Manchanda’s clinical interests include caring for patients with gynaecological cancer, including cancer of the cervix, womb, ovary, vulva and vagina. He has expertise in ultra-radical surgical procedures and laparoscopic surgery. He has a special interest in genetic testing and managing women at high risk of developing gynaecological cancer.

Gynaecology, Oncology
English, Hindi, Punjabi, Urdu
From £250


Prof Ranjit Manchanda is Professor of Gynaecological Oncology at the Wolfson Institute of Preventive Medicine, Barts CRUK Cancer Centre, Queen Mary University of London, and Consultant Gynaecological Oncologist at Barts and the Royal London Hospital. 

Ranjit completed his PhD in Gynaecological Oncology at University College London (UCL). He completed a NIHR Clinical Academic Lectureship at UCL and speciality training in gynaecological oncology at University College London Hospital (UCLH) and St Bartholomew’s Hospital (Barts Health).

He is a NHS Innovation Accelerator (NIA) Fellow. He leads the high-risk women’s Precision Prevention service at Barts Health and is chair of the London Cancer High risk Gynaecological Cancer MDT. He is a member of the NCRI Ovarian Cancer Surgical Sub group. 

He has a keen interest in ultra-radical debulking surgery for ovarian cancer as well as minimal access surgery. He is a member of a number of advisory bodies and oversight committees. 

He is co-Lead for the Cancer Prevention Theme at the Barts CRUK Cancer Centre. He was recently appointed as Speciality Research Lead for Gynaecological Cancer, NIHR North Thames Clinical Research Network (CRN). He is the Integrated Academic Training Programme Director, London Speciality School of Obstetrics & Gynaecology, Health Education England. He is the Lead for the RCOG Advanced Professional Module (APM) in Clinical Research for North Central and North East London. 

He is a member of the International Gynaecological Cancer Society (IGCS) Education Steering Committee and Deputy-Director of the Barts Health RCOG sub-speciality training programme in gynaecological oncology. He has led a number of training initiatives in Gynaecological Oncology across Europe. He has served as President of the European Network of Young Gynaecological Oncologists (ENYGO) and member of the European Society of Gynaecological Oncology (ESGO) Council from 2011 - 2013.

Ranjit’s research interests are focused around Targeted Precision Prevention. This includes population-based germline testing, mainstreaming and precision medicine approaches for risk prediction, stratification, and targeted screening & cancer prevention. 

More information

5 Devonshire Place
London W1G 6HL

  • Professor of Gynaecological Oncology
    Wolfson Institute of Preventive Medicine, Barts Cancer Research UK Centre, Queen Mary University of London
  • Consultant Gynaecological Oncologist
    Barts Health NHS Trust, Royal London Hospital
  • NHS Innovation Accelerator (NIA) Fellow
    NHS Innovation Accelerator
  • Integrated Academic Training Programme Director, Obstetrics & Gynaecology
    London School of Obstetrics & Gynaecology (LSSOG), Health Education England (HEE)
  • Deputy Director Sub-speciality Training Programme, Gynaecological Oncology
    Barts Health NHS Trust
  • Management of high risk women, e.g. BRCA, lynch Syndrome, cowden's syndrome, RAD51C, RAD51D, BRIP1, PALB2
  • Ovarian cancer
  • Vulval cancer
  • Vaginal cancer
  • Endometrial cancer
  • Cervical cancer
  • Management of high risk women
  • Year qualified 1993
  • All India Institute of Medical Sciences (AIIMS), New Delhi, India

Professor Manchanda is the recipient of a number of awards, including:

  • Shyam Agarwal Memorial Oration Award (Dec 2019)
  • NHS Innovation Accelerator Fellowship Award (Mar 2019)
  • Local Clinical Excellence Award (2019)
  • William Blair Bell Memorial Lecture Award (RCOG, 2018)
  • Helen Harris Memorial Trust Travelling Fellowship Award (2011)
  • NIHR Academic Clinical Lecturer award (2010)
  • Indian Council of Medical Research (ICMR) Fellowship award (2000 - 2001)

Multigene Testing in Breast Cancer: Cost-effectiveness Analysis

MedPage Today
Does it make sense to test all women with breast cancer, not just those with certain clinical criteria or a family history?

Breast cancer: Call for genetic screening for all

BBC news
Offering every woman diagnosed with breast cancer genetic screening would save hundreds of lives each year, a study suggests.

All women over 30 should be tested for faulty cancer gene, researchers say

SKY news
Barts Cancer Institute research estimates around 83,000 cancers could be prevented if all women over 30 were screened.

A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer

Authors: Sun L, Brentnall A, Patel S,, Buist DSM, Bowles EJA, Evans DGR, Eccles D, Hopper J, Li S, Southey M, Duffy S, Cuzick J, Dos Santos Silva I, Miners A, Sadique Z, Yang L, Legood R, Manchanda R
Year: 2019
Published by: JAMA Oncology

Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women

Authors: Manchanda R, Patel S, Gordeev VS, Antoniou AC, Smith S, Lee A, Hopper JL, MacInnis RJ, Turnbull C, Ramus SJ, Gayther SA, Pharoah PDP, Menon U, Jacobs I, Legood R4
Year: 2018
Published by: Journal of the National Cancer Institute

Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing

Authors: Manchanda R, Legood R, Burnell M, McGuire A, Raikou M, Loggenberg K, Wardle J, Sanderson S, Gessler S, Side L, Balogun N, Desai R, Kumar A, Dorkins H, Wallis Y, Chapman C, Taylor R, Jacobs C, Tomlinson I, Beller U, Menon U, Jacobs I.
Year: 2014
Published by: Journal of the National Cancer Institute


Contact us

Request an appointment with our world-leading consultants today, or speak to our helpful advisors for tailored advice.